Logo Geneseeq
  • Services
    • Genomic Testing
      • Laboratory Developed Tests (LDT)
        • Solid Tumors
        • Hematologic Malignancies
        • Hereditary Cancers
        • Minimal Residual Disease
      • IVD Kit Solution
      • RUO Kit Solution
    • Research Services
      • Platforms
      • DNA Sequencing
      • RNA Sequencing
      • Other Services
  • Technology
    • Our Technology
    • Publications
  • Partnerships
  • About Us
    • What is Precision Oncology?
    • Our Company
    • Our Team
    • Certificates & Accreditation
  • News
  • Join Us
  • Contact Us
  • Ch|中文
  • Search

October 17, 2023

Geneseeq to present four studies at ESMO 2023

by Geneseeq

August 29, 2023

GENESEEQ TO SHARE EIGHT COLLABORATED STUDIES AT WCLC 2023

by Geneseeq

May 25, 2023

GENESEEQ TO SHOWCASE NEW FINDINGS AT ASCO 2023

by Geneseeq

March 9, 2023

Geneseeq and Collaborators Initiate MOTION Study to Evaluate the Performance of Minimal Residual Disease Test SHIELDING™ in Early-stage Lung Cancer

by GENESEEQ

January 24, 2023

Geneseeq receives CE Marks for MRD and MCED tests.

by GENESEEQ

May 31, 2022

Geneseeq at ASCO 2022

by GENESEEQ

April 27, 2021

Geneseeq and AstraZeneca Collaborate to Build Guangzhou Bio-Diagnostics Innovation Center

by GENESEEQ

Logo Geneseeq

1-647-714-5020
1-800-362-0325
info.toronto@geneseeq.com

Quick Links
  • Services
  • Technology
  • News
  • About Us
Connect
  • Partnerships
  • Join us
  • Contact us
Privacy
  • Privacy Policy
  • Terms of Use
Headquarters

Main Office:
Suite 1802
393 University Avenue
Toronto, Ontario, M5G 1E6
Canada

© 2023 Geneseeq Technology Inc. | A Precision Oncology Company. All rights reserved

Privacy Preference Center

Privacy Preferences